代谢重编程在细胞癌的病变发生和治疗影响
Yifan Zhang1, Shengli Zhang1, Hongbin Sun2
1Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Cell death discovery
|April 19, 2025
概括
细胞癌 (RCC) 的新陈代谢推动了瘤的生长和免疫逃逸. 针对像谷氨胺和脂质合成这样的代谢途径,为这种癌症提供了新的精确治疗策略.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 癌症免疫学 癌症免疫学
背景情况:
- 细胞癌 (RCC) 是一种难以治疗的生殖尿路癌症.
- 代谢重编程是RCC发展的关键,涉及营养使用,脂质合成和谷氨胺依赖.
- 瘤代谢会影响瘤的微环境,导致免疫抑制.
研究的目的:
- 审查RCC代谢的分子基础.
- 探索代谢变化如何驱动RCC进展和治疗耐药性.
- 讨论癌症治疗的潜在代谢标.
主要方法:
- 对RCC代谢的文献进行系统审查.
- 对遗传因素 (VHL/HIF,mTOR) 和表观遗传修饰剂的分析.
- 研究空间代谢区分及其影响.
- 针对代谢酶的治疗策略的评估.
主要成果:
- RCC代谢的特点是超出华堡效应的转变,包括脂质合成代谢和谷氨胺辅助性.
- 瘤内的代谢异质性有助于治疗耐药性.
- 空间代谢区分创造了亲血管和免疫抑制的微域.
- 针对脂质发生和谷氨胺代谢的抑制剂显示出治疗的前景.
结论:
- 针对RCC中的代谢漏洞,如谷氨胺代谢和脂质生成,是一个有前途的治疗途径.
- 将代谢抑制剂与PD-1阻断等免疫疗法结合起来,可能会增强抗瘤免疫力.
- 整合多学科和空间生物学可以指导RCC的精密医学.
相关概念视频
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Adaptive Mechanisms in Cancer Cells
5.5K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.5K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


